Bayesian methods for evidence synthesis in cost-effectiveness analysis (Q36381197)

13 August 2017

1 reference

title

Bayesian methods for evidence synthesis in cost-effectiveness analysis (English)

1 reference

cost-effectiveness analysis

13 August 2017

1 reference

Keith Abrams

4

0 references

Mark Sculpher

2

object named as

Mark Sculpher

1 reference

13 August 2017

A E Ades

1

1 reference

13 August 2017

Alex Sutton

3

1 reference

13 August 2017

Nicola Cooper

5

1 reference

13 August 2017

Nicky Welton

6

1 reference

13 August 2017

Guobing Lu

7

1 reference

13 August 2017

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

24

1 reference

13 August 2017

1-19

1 reference

13 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200624010-00001

13 August 2017

0 references

cites work

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200624010-00001

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200624010-00001

Bayesian subset analysis in a colorectal cancer clinical trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200624010-00001

Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials

21 January 2018

1 reference

12 December 2020

Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?

1 reference

12 December 2020

Multiple-outcome meta-analysis of clinical trials

1 reference

12 December 2020

Generalized synthesis of evidence and the threat of dissemination bias. the example of electronic fetal heart rate monitoring (EFM).

1 reference

12 December 2020

How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS.

1 reference

12 December 2020

Multivariate meta-analysis.

1 reference

12 December 2020

Assessing apparent treatment--covariate interactions in randomized clinical trials

1 reference

12 December 2020

Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials

1 reference

12 December 2020

A rational framework for decision making by the National Institute For Clinical Excellence (NICE).

1 reference

12 December 2020

Meta-analytic tools for medical decision making: a practical guide

1 reference

12 December 2020

Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke

1 reference

12 December 2020

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

12 December 2020

Bayesian cost-effectiveness analysis. An example using the GUSTO trial.

1 reference

12 December 2020

Meta-analysis in clinical trials

1 reference

12 December 2020

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

12 December 2020

Hierarchical models in generalized synthesis of evidence: an example based on studies of breast cancer screening

1 reference

12 December 2020

A new form of meta-analysis for combining results from randomized clinical trials and medical-practice databases.

1 reference

12 December 2020

Bayesian methods in meta-analysis and evidence synthesis

1 reference

12 December 2020

Bayesian Subset Analysis

1 reference

12 December 2020

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

12 December 2020

A comparison of observational studies and randomized, controlled trials

1 reference

12 December 2020

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

1 reference

12 December 2020

A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention.

1 reference

12 December 2020

On meta-analytic assessment of surrogate outcomes.

1 reference

12 December 2020

Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease

1 reference

12 December 2020

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

1 reference

12 December 2020

Markov chain Monte Carlo estimation of a multiparameter decision model: consistency of evidence and the accurate assessment of uncertainty.

1 reference

12 December 2020

A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis

1 reference

12 December 2020

Combination of direct and indirect evidence in mixed treatment comparisons

1 reference

12 December 2020

Meta-analysis of multitreatment studies

1 reference

12 December 2020

Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials

1 reference

12 December 2020

Health economic guidelines--similarities, differences and some implications

1 reference

12 December 2020

A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence.

1 reference

12 December 2020

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

12 December 2020

Inter-study differences: how should they influence the interpretation and analysis of results?

1 reference

12 December 2020

Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses

1 reference

12 December 2020

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

1 reference

12 December 2020

When are observational studies as credible as randomised trials?

1 reference

12 December 2020

Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models

1 reference

12 December 2020

Borrowing strength from external trials in a meta-analysis.

1 reference

12 December 2020

Meta-analysis for the evaluation of potential surrogate markers.

1 reference

12 December 2020

Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section.

1 reference

12 December 2020

Meta-analysis of multiple outcomes by regression with random effects.

1 reference

12 December 2020

Probabilistic analysis of decision trees using Monte Carlo simulation

1 reference

12 December 2020

A Bayesian approach to sensitivity analysis.

1 reference

12 December 2020

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

1 reference

12 December 2020

Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis

1 reference

12 December 2020

Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach

1 reference

12 December 2020

A perspective on surrogate endpoints in controlled clinical trials

1 reference

12 December 2020

Choosing between randomised and non-randomised studies: a systematic review

1 reference

12 December 2020

A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder

1 reference

12 December 2020

Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.

1 reference

12 December 2020

Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches.

1 reference

12 December 2020

10.2165/00019053-200624010-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

0 references

1 reference